



President Francisco X REAL
 Epithelial Carcinogenesis Group
 Molecular Pathology Programme
 Centro Nacional de Investigaciones Oncológicas
 Melchor Fernández Almagro 3
 28029-Madrid
 Spain
 Tel: +34 917 328 000

Secretary Peter HEGYI
 First Department of Medicine
 Faculty of Medicine
 University of Szeged
 8-10 Koranyi fasor
 H-6720, Szeged
 Hungary
 Tel: +36-62-545200
 Fax: +36-62-545185

Treasurer Rolf GRAF
 Department of Surgery, Div. of
 Visceral & Transplant Surgery
 University Hospital
 Rämistrasse 100
 8091 Zurich
 Switzerland
 Tel: +41-44-2552071
 Fax: +41-44-2554449

APPLICATION FORM

for Abstract Selection Committee Member (representing Basic Science) of the European
 Pancreatic Club (EPC)

1	Personal data	Name: BOUSQUET Corinne Username (www.e-p-c.org): BOUSQUET Corinne Country: FRANCE National Society: CLUB FRANCAIS DU PANCREAS (board member)
2	Membership	List of years when the applicant was member of EPC (if applicable): 2015 List of years when the applicant attended the annual EPC meeting (if applicable): 2008 - 2010 - 2013 - 2014 - 2015 List of years when the applicant had communication(s) at the annual main or satellite EPC meeting: 2010 (poster) - 2013 (oral) - 2014 (oral) - 2015 (oral)
3	Publications	List of the best 5 original/review papers in international journals: In the 2 last years : Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16. Chalabi-Dchar M, Cassant-Sourdy S, Duluc C, <i>et al.</i> , Bousquet C. Gastroenterology. 2015 Feb 12. pii: S0016-5085(15)00200-0. Pharmacological targeting of the protein synthesis mTOR/4E-BP1 pathway in cancer-associated fibroblasts abrogates pancreatic tumour chemoresistance. Duluc C, Moatassim-Billah S, Chalabi-Dchar M, <i>et al.</i> , Bousquet C. EMBO Mol Med. 2015 Apr 1. pii: e201404346. doi: 10.15252/emmm.201404346. [Epub ahead of print] Somatostatin analogs: does pharmacology impact antitumor efficacy? Chalabi M, Duluc C, Caron P, <i>et al.</i> , Bousquet C. Trends Endocrinol Metab. 2014 Mar;25(3):115-27. Review. Dual roles of hemidesmosomal proteins in the pancreatic epithelium: the phosphoinositide 3-kinase decides.

		<p>Laval S, Laklai H, Fanjul M, <i>et al.</i>, Bousquet C. Oncogene. 2014 Apr 10;33(15):1934-44.</p> <p>Pancreatic tumours escape from translational control through 4E-BP1 loss. Martineau Y, Azar R, Müller D, <i>et al.</i>, Bousquet C, Pyronnet S. Oncogene. 2014 Mar 13;33(11):1367-74.</p>
4	Previous positions at EPC or UEG	none

The applicant confirms that she/he

- has read the Open call for Abstract Selection Committee Member (Basic Science) position and fully accept its content
- has adequate time resources for volunteer work
- has good command of spoken and written English

Name BOUSQUET Corinne

Date May 15th, 2015





Corinne BOUSQUET

Director of Research, INSERM U1037, Cancer Research Center of Toulouse (CRCT) - FRANCE

Co-Leader of the Team 6 "Protein synthesis & secretion in carcinogenesis"

<http://www.crct-inserm.fr/06-s-pyronnet-c-bousquet-protein-synthesis-secretion-in-carcinogenesis-548.html>

Researcher ID: P-2917-2014

Mail: corinne.bousquet@inserm.fr - Tel: (33-5) 82 74 16 53

• **PERSONAL INFORMATION**

BOUSQUET Corinne

French nationality

Born of the 30th of September, 1970

Married - 4 children

• **EDUCATION**

2011 Capacitation as Research Director, University of Toulouse, France

2001 Capacitation in animal experimentation: state diploma, National Veterinary School of Toulouse, France

1999 Thesis in Veterinarian Medicine, Laureate of University of Toulouse, France

1999 (Dec 20th) PhD in Biological Sciences, Specialty in Molecular and Cellular Biology & Pharmacology, grade A+, congratulations of the jury, University of Toulouse, France (PhD under the supervision of P. S. Melmed, Cedars Sinai Medical Center, Los Angeles USA)

1995 Master in Molecular Pharmacology, University of Toulouse, France

1994 Degree in Veterinarian Medicine, National Veterinary School of Toulouse, France

• **PREVIOUS POSITIONS**

2004 – 2012 Research Scientist 1st class, INSERM U858, Institute of Molecular Medicine, Toulouse

2001 – 2004 Research Scientist 2nd class, INSERM U531, Digestive Biology & Pathology Laboratory, Toulouse, France

• **FELLOWSHIPS AND AWARDS**

Fellowships

1999 – 2000 Assistant Professor, Department of Endocrinology & Metabolism, Cedars Sinai Medical Center, Los Angeles, USA, Research theme: "Mechanisms of immuno-neuroendocrine interfacing in the pituitary"

1996 – 1999 PhD Student, Department of Endocrinology & Metabolism, Cedars Sinai Medical Center, Los Angeles, USA, Supervisor: Pr. S. Melmed, Research theme: "Negative regulation of pituitary corticotroph function". My University of PhD inscription was Toulouse but I was trained as a PhD student by Pr. S. Melmed (PhD in co-direction with INSERM U151 headed by Dr. N. Vaysse).

1994 – 1995 Master Student, INSERM U151, Digestive Biology & Pathology Laboratory, Toulouse, France, Supervisor: Dr. C. Susini, Research theme: "Antiproliferative signals mediated by somatostatin and its receptors"

Awards

2012 Best project price of the French Group for Endocrine Tumors (GTE)

- 2010 Project selected and communicated by french Research Association of Cancer (ARC)
- 2006 Best project price of the French Endocrine Society (SFE / PFIZER)
- 2005 Best Abstract Novartis Young Investigator Meeting, Barcelona
- 2002 French INSERM Contrat d'Interface Award
- 1995 Ministère Français de la Recherche et des Technologies studentship.

- **SUPERVISION OF GRADUATE STUDENTS AND POSTDOCTORAL FELLOWS**

- 2002–2015 Supervision of 3 Postdocs / 8 PhD (5 completed and 3 ongoing) / 5 Master Students / 5 under-Graduate Students (University of Toulouse France & Rabat Morocco)

- **TEACHING ACTIVITIES**

- 2004 – 2005 Master in HepatoGastroenterology, University Paris 7, "Molecular Basis of Pancreatic Cancer": 4 h /year
- 2004 – 2015 Master in Oncology, University Paul Sabatier, Toulouse, "Epithelial to Mesenchymal Transition & Invasion in Tumors - role of the microenvironment": 20 h /year

- **ORGANISATION OF SCIENTIFIC MEETINGS**

- 2015 Organizer of the International "Pancreatic Cancer Symposium", Marseille France (250 pers.)
- 2015 Co-organizer of the "PI3K Symposium", Toulouse France (100 pers.)
- 2011 - 2015 Organizer of the annual French Pancreatic Club, France (100 pers.)
- 2014 Organizer of the Symposium on Pancreatic Cancer, Paris France (100 pers.)
- 2014 Faculty Member of the International "Pancreatic Cancer Forum", Munich Germany (250 pers.)
- 2013 Organizer of the "Cancer-Associated Fibroblasts & Tumor cells: Dangerous liaisons" Symposium, Toulouse France (120 pers.)
- 2004 Organizer of the International "Regulatory Peptides" Meeting, Toulouse France (400 pers.)

- **INSTITUTIONAL RESPONSABILITIES**

- 2011 –2015 Elected Faculty member at Toulouse Cancer Research Center Executive Board
- 2013 – 2015 Member of the scientific grant review committee for the "Ligue Contre le Cancer", France
- 2014 – 2015 Member of the scientific grant review committee for the "Cancéropole Provence-Alpes-Côte d'Azur", France
- 2012 – 2015 IUPHAR somatostatin subcommittee Member
- 2013 Examiner in 1 "Capacitation as Research Director" Committee, University of Lyon, France
- 2014 – 2015 Examiner in 2 "PhD Defence" Committees, University of Marseille, France
- 2010– 2011 Examiner in 2 "European PhD Defence" Committees, University of Cordoba, Spain
- 2011 – 2015 Advisor in 4 "Graduate Student" Committees, Universities of Toulouse, Marseille, Montpellier, France

- **MEMBERSHIPS OF SCIENTIFIC SOCIETIES**

- 2015 – 2016 Elected Associate Treasurer, Research Network "Société Française d'Endocrinology"(SFE)

- 2011 – 2016 Elected Treasurer and Member, Research Network “Club Français du Pancréas” (CFP)
- 2014 – 2015 Member, Research Network "French Association for Pancreatic Cancer Research" (AFRCP)
- 2014 – 2015 Member, Research Network “American Association for Cancer Research” (AACR)
- 2013 – 2015 Member, Research Network “European Pancreatic Club” (EPC)
- 2001 – 2015 Member, french Research Network “Epithelial Digestive Cell study Club” (CECED)

• **PUBLICATIONS**

Citations and scientific impact: **H Index: 21**;

Sum of times cited (without self-citations): **1,366**;

Average citation per item: **37.87**

Publications: A total of **42** research articles were published in peer-reviewed international multi-disciplinary journals, not including conference proceedings. On that number, **10** research articles were published as a senior (last) and/or corresponding author, and **10** as first author.

Major publications:

- **Bousquet C**, Susini C, Melmed S. Inhibitory roles for SHP-1 and SOCS-3 following pituitary proopiomelanocortin by leukemia inhibitory factor. **J Clin Invest**, 1999, 104(9):1277-1285. Number of citation: 70
- Auernhammer CJ, **Bousquet C**. Melmed S. Autoregulation of pituitary corticotroph SOCS-3 expression - Characterization of the murine SOCS-3 promoter. **Proc Natl Acad Sci USA**, 1999, 96:6964-6969. Number of citation: 214
- Bousquet C, Zatelli MC, Melmed S. Direct regulation of pituitary proopiomelanocortin by STAT3 provides a novel mechanism for immuno-neuroendocrine interfacing. *J Clin Invest*, 2000, 106(11): 1417-25. Number of citation: 63
- Guillermet J, Saint-Laurent N, Rochaix P, Levade T, Cuvelier O, Pradayrol L, Buscail L, Susini C, **Bousquet C**. Somatostatin sst2 receptor sensitizes pancreatic cancer cells to death ligand-induced apoptosis. **Proc Natl Acad Sci USA**, 2003, 100(1), 155-60. Number of citation: 92
- **Bousquet C**, Guillermet-Guibert J, Saint-Laurent N, Archer-Lahlou E, Lopez F, Fanjul M, Ferrand A, Fourmy D, Pichereaux C, Monsarrat B, Pradayrol L, Estève JP, Susini C. Direct binding of p85 to sst2 somatostatin receptor reveals a novel mechanism for inhibiting PI3K pathway. **EMBO J**. 2006, 25(17):3943-54. Number of citation: 41
- Guillermet-Guibert J, Saint-Laurent N, Davenne L, Rochaix P, Cuvillier O, Culler MD, Pradayrol L, Buscail L, Susini C, **Bousquet C**. Novel synergistic mechanism for sst2 somatostatin and TNFalpha receptors to induce apoptosis: crosstalk between NF-kappaB and JNK pathways. **Cell Death Differ**. 2007 Feb;14(2):197-208. Number of citation: 23
- Guillermet-Guibert J, Davenne L, Pchejetski D, Saint-Laurent N, Brizuela L, Guilbeau-Frugier C, Delisle MB, Cuvillier O, Susini C, **Bousquet C**. Targeting the sphingolipid metabolism to defeat pancreatic cancer cell resistance to the chemotherapeutic gemcitabine drug. **Mol Cancer Ther**. 2009, 8(4):809-20. Number of citation: 40
- Laklai H, Laval S, Dumartin L, Rochaix P, Hagedorn M, Bikfalvi A, Le Guellec S, Delisle MB, Schally AV, Susini C, Pyronnet S, **Bousquet C**. Thrombospondin-1 is a critical effector of oncosuppressive activity of sst2 somatostatin receptor on pancreatic cancer. **Proc Natl Acad Sci U S A**. 2009, 106(42):17769-74.

- Najib S, Saint-Laurent N, Estève JP, Schulz S, Boutet-Robinet E, Fourmy D, Lättig J, Mollereau C, Pyronnet S, Susini C, **Bousquet C**. A switch of GPCR binding preference from PI3K-p85 to filamin-A negatively controls the PI3K pathway. **Mol Cell Biol**. 2012, 32(5):1004-16.
- Laval S, Laklai H, Fanjul M, Pucelle M, Laurell H, Billon-Galés A, Le Guellec S, Delisle MB, Sonnenberg A, Susini C, Pyronnet S, **Bousquet C**. Dual roles of hemidesmosomal proteins in the pancreatic epithelium: the phosphoinositide 3-kinase decides. **Oncogene**. 2014, 33(15):1934-44.
- Chalabi M, Duluc C, Caron P, Vezzosi D, Guillermet-Guibert J, Pyronnet S, **Bousquet C**. Somatostatin analogs: does pharmacology impact antitumor efficacy? **Trends Endocrinol Metab**. 2014, 25(3):115-27. Review
- Chalabi-Dchar M, Cassant-Sourdy S, Duluc C, Fanjul M, Lulka H, Samain R, Roche C, Breibach F, Delisle MB, Poupot M, Dufresne M, Shimaoka T, Yonehara S, Mathonnet M, Pyronnet S, **Bousquet C**. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16. **Gastroenterology**. 2015 Feb 12. pii: S0016-5085(15)00200-0. doi: 10.1053/j.gastro.2015.02.009. [Epub ahead of print]
- Duluc C, Moatassim-Billah S, Chalabi-Dchar M, Perraud A, Samain R, Breibach F, Gayral M, Cordelier P, Delisle MB, Bousquet-Dubouch MP, Tomasini R, Schmid H, Mathonnet M, Pyronnet S, Martineau Y, **Bousquet C**. Pharmacological targeting of the protein synthesis mTOR/4E-BP1 pathway in cancer-associated fibroblasts abrogates pancreatic tumour chemoresistance. **EMBO Mol Med**. 2015 Apr 1. pii: e201404346. doi: 10.15252/emmm.201404346. [Epub ahead of print]

• **LECTURES (INTERNATIONAL):**

Meetings (under invitation):

- European NeuroEndocrine Association (Enea), Liège (2010): New PI3K targets as key players for the antitumoral actions of the somatostatin receptor sst2.
- VI Simposio GETNE, Santiago de Compostela (2010): Antiproliferative effects of somatostatin analogs.
- International Congress of Endocrinology ICE/ECE Florence (2012): Somatostatin receptor and filamin, a developing story.
- Third annual meeting of the Middle Eastern Association for Cancer Research, Rabat, Morocco (2013): Role for somatostatin receptors in the biology of pancreatic adenocarcinoma: Therapeutic interests?
- 2nd Pancreatic Cancer Forum Meeting, Faculty Member, Munich (2014): Will current basic research programmes produce the answers we really need?

Seminars:

- Cedars-Sinai Research Institute, Los Angeles CA (2000): Direct regulation of pituitary proopiomelanocortin by STAT3 provides a novel mechanism for immuno-neuroendocrine interfacing.
- NOVARTIS, Bâles Suisse (2009): Molecular mechanisms for the oncosuppressive role of somatostatin receptor sst2 : lesson from pancreatic cancer.

- Instituto Maimónides de Investigación Biomédica de Córdoba – IMIBIC - Spain (2010): Molecular mechanisms for the oncosuppressive role of somatostatin receptor sst2 : lesson from pancreatic cancer.
- Cedars-Sinai Research Institute, Los Angeles CA (2014): Role for somatostatin receptors in the biology of pancreatic adenocarcinoma: Therapeutic interests?
- Université Catholique de Louvain, de Duve Institute, Brussels (2015): Pancreatic cancer and its microenvironment: Models of study and pharmacological targeting.

Under abstract selection (oral communications):

- Endocrine Society Annual Meeting, New Orleans LA (1998): Pituitary corticotroph SOCS-3: novel intracellular regulation of leukemia-inhibitory factor-mediated proopiomelanocortin gene expression and adrenocorticotropin secretion.
- Endocrine Society Annual Meeting, San Diego CA (1999): Autoregulation of pituitary corticotroph SOCS-3 expression - Characterization of the murine SOCS-3 promoter.
- Endocrine Society Annual Meeting, Toronto, Canada (2000): Direct binding of LIF-induced STAT3 to the POMC promoter: novel molecular mechanism for LIF and CRH synergy on corticotroph ACTH secretion.
- Endocrine Society Annual Meeting, Denver CO (2001): cAMP neuropeptide agonists induce pituitary suppressor of cytokine signaling-3: novel negative feedback mechanism for corticotroph cytokine action.
- American Gastroenterological Association, San Francisco CA (2002): Somatostatin SST2 Receptor Sensitizes Pancreatic Cancer Cells to Death Ligand-Induced Apoptosis.
- American Gastroenterological Association, New Orleans LA (2004): Critical role for PI3K subunit p85 as a direct effector of somatostatin receptor subtype 2-mediated induction of apoptosis in pancreatic cancer cells.
- 16th International Symposium on Regulatory Peptides, Hakone, Japan, (2006): Identification of new somatostatin receptor sst2 targets involved in the negative effect of somatostatin on tumor angiogenesis and invasiveness.
- 91st Annual Meeting of The Endocrine Society, Washington DC (2009): Forced hemidesmosome assembly as a novel mechanism for somatostatin receptor sst2 tumor suppressive activity in pancreatic cancer.
- 17th International Symposium on Regulatory Peptides, Santa Barbara, USA (2009): Identification of new somatostatin receptor sst2 targets involved in the negative effect of somatostatin on tumor angiogenesis and invasiveness.
- 5th International Conference on Tumor Microenvironment: Progression, Therapy, and Prevention, Versailles (2009): Forced hemidesmosome assembly as a novel mechanism for somatostatin receptor sst2 tumor suppressive activity in pancreatic cancer.
- European Pancreatic Club, Zurich (2013): Therapeutic interest to target the Phosphoinositide-3-Kinase (PI3K)-mTOR pathway in activated Pancreatic Stellate Cells.
- European Pancreatic Club, Southampton (2014): Pharmacological targeting of protein synthesis in cancer-associated fibroblasts abrogates pancreatic tumor chemoresistance.
- AACR Conference "Cellular Heterogeneity in the Tumor Microenvironment", San Diego (2014): Pharmacological targeting of protein synthesis in cancer-associated fibroblasts abrogates pancreatic tumor chemoresistance.

- European Pancreatic Club, Toledo (2015): Anti-metastatic potential of somatostatin analog SOM230 Pasireotide in pancreatic cancer: Indirect pharmacological targeting of Cancer-Associated Fibroblasts.